FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2344014912> ?p ?o ?g. }

• W2344014912 endingPage "1060" @default.
• W2344014912 startingPage "1053" @default.
• W2344014912 abstract "No AccessJournal of UrologyAdult Urology1 Oct 2016Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy Allison H. Feibus, Oliver Sartor, Krishnarao Moparty, Kevin Chagin, Michael W. Kattan, Elisa Ledet, Justin Levy, Benjamin Lee, Raju Thomas, and Jonathan L. Silberstein Allison H. FeibusAllison H. Feibus Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana More articles by this author , Oliver SartorOliver Sartor Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author , Krishnarao MopartyKrishnarao Moparty Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana More articles by this author , Kevin ChaginKevin Chagin Department of Quantitative Health Sciences, Cleveland Cancer Foundation, Cleveland, Ohio More articles by this author , Michael W. KattanMichael W. Kattan Department of Quantitative Health Sciences, Cleveland Cancer Foundation, Cleveland, Ohio Financial interest and/or other relationship with Exosome Diagnostics. More articles by this author , Elisa LedetElisa Ledet Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author , Justin LevyJustin Levy Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author , Benjamin LeeBenjamin Lee Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana Financial interest and/or other relationship with Porges Coloplast. More articles by this author , Raju ThomasRaju Thomas Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana More articles by this author , and Jonathan L. SilbersteinJonathan L. Silberstein Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.04.075AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Prostate specific antigen has decreased performance characteristics for the detection of prostate cancer in African-American men. We evaluated urinary PCA3 and TMPRSS2:ERG in a racially diverse group of men. Materials and Methods: After institutional review board approval, post-examination urine was prospectively collected before prostate biopsy. PCA3 and TMPRSS2:ERG RNA copies were quantified using transcription mediated amplification assays (Hologic, San Diego, California). Prediction models were created using standard of care variables (age, race, family history, prior biopsy, abnormal digital rectal examination) plus prostate specific antigen. Decision curve analysis was performed to compare the net benefit of PCA3 and TMPRSS2:ERG. Results: Of 304 patients 182 (60%) were African-American and 139 (46%) were diagnosed with prostate cancer (69% African-American). PCA3 and TMPRSS2:ERG scores were greater in men with prostate cancer, 3 or more cores, 33.3% or more cores, greater than 50% involvement of greatest biopsy core and Epstein significant prostate cancer (p <0.01). PCA3 added to the standard of care plus prostate specific antigen model for the detection of any prostate cancer in the overall cohort (0.747 vs 0.677, p <0.0001) in African-American men only (0.711 vs 0.638, p=0.0002) and nonAfrican-American men (0.781 vs 0.732, p=0.0016). PCA3 added to the model for the prediction of high grade prostate cancer for the overall cohort (0.804 vs 0.78, p=0.0002) and African-American men only (0.759 vs 0.717, p=0.0003) but not nonAfrican-American men. Decision curve analysis demonstrated improvement with the addition of PCA3. For African-American men TMPRSS2:ERG did not improve concordance statistics for the detection of prostate cancer. Conclusions: For African-American men urinary PCA3 improves the ability to predict the presence of any and high grade prostate cancer. However, the TMPRSS2:ERG urinary assay does not add significantly to standard tools. References 1 : Cancer statistics. CA Cancer J Clin2013; 63: 11. Google Scholar 2 : Explaining racial differences in prostate cancer in the United States: sociology or biology?. Prostate2005; 62: 243. Google Scholar 3 : Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol2007; 52: 1309. Google Scholar 4 : Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med1991; 324: 1156. Crossref, Medline, Google Scholar 5 : Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA1995; 274: 1277. Crossref, Medline, Google Scholar 6 : Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst1997; 89: 134. Google Scholar 7 : Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst1998; 90: 756. Google Scholar 8 : Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2012; 157: 120. Google Scholar 9 : Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009; 360: 1320. Google Scholar 10 : The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Contol Clin Trials, suppl.2000; 21: 251S. Google Scholar 11 : PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol2008; 179: 1587. Link, Google Scholar 12 : APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem2006; 52: 1089. Google Scholar 13 : Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat2008; 62: 314. Google Scholar 14 : Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol2016; 70: 45. Google Scholar 15 : Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med1996; 335: 304. Google Scholar 16 : Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng/ml. J Urol2000; 163: 1467. Link, Google Scholar 17 : The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting. BJU Int2011; 108: 1728. Google Scholar 18 : Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med2011; 3: 94ra72. Google Scholar 19 : PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology2007; 69: 532. Google Scholar 20 : TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate2011; 71: 489. Google Scholar 21 : Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology2012; 80: 749. Google Scholar 22 : Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev2013; 22: 891. Google Scholar 23 : Predominance of ERG-negative high-grade prostate cancers in African American men. Mol Clin Oncol2014; 2: 982. Google Scholar 24 : Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res2014; 20: 4925. Google Scholar 25 : Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res2007; 13: 5103. Google Scholar 26 : Active surveillance of African American men. Urology2014; 84: 1255. Google Scholar 27 : Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol2015; 33: 272. Google Scholar 28 : Admixture mapping of prostate cancer in African Americans participating in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate2014; 74: 1. Google Scholar 29 : Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute’s Community Cancer Centers Program. Cancer2014; 120: 877. Google Scholar © 2016 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byPunnen S, Freedland S, Polascik T, Loeb S, Risk M, Savage S, Mathur S, Uchio E, Dong Y and Silberstein J (2017) A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American MenJournal of Urology, VOL. 199, NO. 6, (1459-1463), Online publication date: 1-Jun-2018.Taneja S (2017) Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate CancerJournal of Urology, VOL. 198, NO. 6, (1210-1211), Online publication date: 1-Dec-2017. Volume 196Issue 4October 2016Page: 1053-1060 Advertisement Copyright & Permissions© 2016 by American Urological Association Education and Research, Inc.KeywordshumanAfrican Americansprostate cancer antigen 3prostatic neoplasmsbiomarkersbiopsyAcknowledgmentsHologic GenProbe, Inc. performed all PCA3 and TMPRSS2:ERG urine assays in the study without charge.MetricsAuthor Information Allison H. Feibus Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana More articles by this author Oliver Sartor Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author Krishnarao Moparty Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana More articles by this author Kevin Chagin Department of Quantitative Health Sciences, Cleveland Cancer Foundation, Cleveland, Ohio More articles by this author Michael W. Kattan Department of Quantitative Health Sciences, Cleveland Cancer Foundation, Cleveland, Ohio Financial interest and/or other relationship with Exosome Diagnostics. More articles by this author Elisa Ledet Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author Justin Levy Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana More articles by this author Benjamin Lee Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana Financial interest and/or other relationship with Porges Coloplast. More articles by this author Raju Thomas Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana More articles by this author Jonathan L. Silberstein Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana Division of Urology, Department of Surgery, Southeast Louisiana Veterans Health Care Services, New Orleans, Louisiana More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2344014912 created "2016-06-24" @default.
• W2344014912 creator A5001454707 @default.
• W2344014912 creator A5018492666 @default.
• W2344014912 creator A5029609253 @default.
• W2344014912 creator A5041731855 @default.
• W2344014912 creator A5053552337 @default.
• W2344014912 creator A5058467164 @default.
• W2344014912 creator A5067513263 @default.
• W2344014912 creator A5071904385 @default.
• W2344014912 creator A5073246821 @default.
• W2344014912 creator A5080304698 @default.
• W2344014912 date "2016-10-01" @default.
• W2344014912 modified "2023-09-27" @default.
• W2344014912 title "Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy" @default.
• W2344014912 cites W1573867559 @default.
• W2344014912 cites W1588377047 @default.
• W2344014912 cites W1594883903 @default.
• W2344014912 cites W1972288064 @default.
• W2344014912 cites W1986697561 @default.
• W2344014912 cites W2005304320 @default.
• W2344014912 cites W2024097324 @default.
• W2344014912 cites W2027142966 @default.
• W2344014912 cites W2038397362 @default.
• W2344014912 cites W2053583905 @default.
• W2344014912 cites W2063878321 @default.
• W2344014912 cites W2077433520 @default.
• W2344014912 cites W2091508328 @default.
• W2344014912 cites W2095761465 @default.
• W2344014912 cites W2097876373 @default.
• W2344014912 cites W2098905361 @default.
• W2344014912 cites W2106869018 @default.
• W2344014912 cites W2112044462 @default.
• W2344014912 cites W2134793522 @default.
• W2344014912 cites W2139366934 @default.
• W2344014912 cites W2144469127 @default.
• W2344014912 cites W2145486801 @default.
• W2344014912 cites W2146294552 @default.
• W2344014912 cites W2146901330 @default.
• W2344014912 cites W2150931597 @default.
• W2344014912 cites W2153853712 @default.
• W2344014912 cites W2161817637 @default.
• W2344014912 cites W2319972791 @default.
• W2344014912 cites W2335679869 @default.
• W2344014912 doi "https://doi.org/10.1016/j.juro.2016.04.075" @default.
• W2344014912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27140073" @default.
• W2344014912 hasPublicationYear "2016" @default.
• W2344014912 type Work @default.
• W2344014912 sameAs 2344014912 @default.
• W2344014912 citedByCount "17" @default.
• W2344014912 countsByYear W23440149122016 @default.
• W2344014912 countsByYear W23440149122017 @default.
• W2344014912 countsByYear W23440149122018 @default.
• W2344014912 countsByYear W23440149122019 @default.
• W2344014912 countsByYear W23440149122020 @default.
• W2344014912 countsByYear W23440149122021 @default.
• W2344014912 countsByYear W23440149122022 @default.
• W2344014912 crossrefType "journal-article" @default.
• W2344014912 hasAuthorship W2344014912A5001454707 @default.
• W2344014912 hasAuthorship W2344014912A5018492666 @default.
• W2344014912 hasAuthorship W2344014912A5029609253 @default.
• W2344014912 hasAuthorship W2344014912A5041731855 @default.
• W2344014912 hasAuthorship W2344014912A5053552337 @default.
• W2344014912 hasAuthorship W2344014912A5058467164 @default.
• W2344014912 hasAuthorship W2344014912A5067513263 @default.
• W2344014912 hasAuthorship W2344014912A5071904385 @default.
• W2344014912 hasAuthorship W2344014912A5073246821 @default.
• W2344014912 hasAuthorship W2344014912A5080304698 @default.
• W2344014912 hasConcept C103796816 @default.
• W2344014912 hasConcept C118487528 @default.
• W2344014912 hasConcept C121608353 @default.
• W2344014912 hasConcept C126322002 @default.
• W2344014912 hasConcept C126894567 @default.
• W2344014912 hasConcept C2775934546 @default.
• W2344014912 hasConcept C2776235491 @default.
• W2344014912 hasConcept C2778042024 @default.
• W2344014912 hasConcept C2779134260 @default.
• W2344014912 hasConcept C2780192828 @default.
• W2344014912 hasConcept C2780827179 @default.
• W2344014912 hasConcept C2781217009 @default.
• W2344014912 hasConcept C3008058167 @default.
• W2344014912 hasConcept C524204448 @default.
• W2344014912 hasConcept C71924100 @default.
• W2344014912 hasConcept C77411442 @default.
• W2344014912 hasConcept C87874733 @default.
• W2344014912 hasConceptScore W2344014912C103796816 @default.
• W2344014912 hasConceptScore W2344014912C118487528 @default.
• W2344014912 hasConceptScore W2344014912C121608353 @default.
• W2344014912 hasConceptScore W2344014912C126322002 @default.
• W2344014912 hasConceptScore W2344014912C126894567 @default.
• W2344014912 hasConceptScore W2344014912C2775934546 @default.
• W2344014912 hasConceptScore W2344014912C2776235491 @default.
• W2344014912 hasConceptScore W2344014912C2778042024 @default.
• W2344014912 hasConceptScore W2344014912C2779134260 @default.
• W2344014912 hasConceptScore W2344014912C2780192828 @default.
• W2344014912 hasConceptScore W2344014912C2780827179 @default.
• W2344014912 hasConceptScore W2344014912C2781217009 @default.
• W2344014912 hasConceptScore W2344014912C3008058167 @default.

• next